Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening

被引:11
|
作者
Zhou, Yeheng [1 ,2 ]
Peng, Jiale [1 ]
Li, Penghua [1 ]
Du, Haibo [1 ]
Li, Yaping [1 ]
Li, Yingying [1 ]
Zhang, Li [1 ]
Sun, Wei [2 ]
Liu, Xingyong [1 ]
Zuo, Zhili [1 ,2 ]
机构
[1] Sichuan Univ Sci & Engn, Sch Chem Engn, Zigong, Peoples R China
[2] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China
关键词
IDO1; Molecular docking; HipHop pharmacophore; 3D-QSAR; PAINS; PHENYL BENZENESULFONYLHYDRAZIDES; THERAPEUTIC TARGET; CRYSTAL-STRUCTURES; DERIVATIVES; DOCKING; MECHANISM;
D O I
10.1016/j.compbiolchem.2018.11.024
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this study, a combination of virtual screening methods were utilized to identify novel potential indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. A series of IDOL potential inhibitors were identified by a combination of following steps: Lipinski's Rule of Five, Veber rules filter, molecular docking, HipHop pharmacophores, 3D-Quantitative structure activity relationship (3D-QSAR) studies and Pan-assay Interference Compounds (PAINS) filter. Three known categories of IDO1 inhibitors were used to constructed pharmacophores and 3D-QSAR models. Four point pharmacophores (RI-IDA) of IDOL inhibitors were generated from the training set. The 3D-QSAR models were obtained using partial least squares (PLS) analyze based on the docking conformation alignment from the training set. The leave-one-out correlation (q(2)) and non-cross-validated correlation coefficient (r(pred)(2)) of the best CoMFA model were 0.601 and 0.546, and the ones from the best CoMSIA model were 0.506 and 0.541, respectively. Six hits from Specs database were identified and analyzed to confirm their binding modes and key interactions to the amino acid residues in the protein. This work may provide novel backbones for new generation of inhibitors of IDOL.
引用
收藏
页码:306 / 316
页数:11
相关论文
共 50 条
  • [21] Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold
    Brant, Michael G.
    Goodwin-Tindall, Jake
    Stover, Kurt R.
    Stafford, Paul M.
    Wu, Fan
    Meek, Autumn R.
    Schiavini, Paolo
    Wohnig, Stephanie
    Weaver, Donald F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (02): : 131 - 136
  • [22] Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Williams, David K.
    Markwalder, Jay A.
    Balog, Aaron J.
    Chen, Bin
    Chen, Libing
    Donnell, Jennifer
    Haque, Lauren
    Hart, Amy C.
    Mandal, Sunil K.
    Nation, Andrew
    Shan, Weifang
    Vite, Gregory D.
    Covello, Kelly
    Hunt, John T.
    Jure-Kunkel, Maria N.
    Seitz, Steven P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (04) : 732 - 736
  • [23] Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Lee, Dong-Ho
    Lee, Joo-Youn
    Jeong, Jieun
    Kim, Miok
    Lee, Kyung Won
    Jang, Eunseo
    Ahn, Sunjoo
    Lee, Chang Hoon
    Hwang, Jong Yeon
    MOLECULES, 2017, 22 (11):
  • [24] A novel class of inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) with potential for the treatment of cancer
    Ching, Lai-Ming
    Palmer, Brian D.
    Tomek, Petr
    Flanagan, Jack U.
    Henare, Kimiora
    CANCER RESEARCH, 2015, 75
  • [25] ACTIVATION OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) IN PATIENTS WITH SYSTEMIC SCLEROSIS
    Del Papa, N.
    Filippini, P.
    De Cristofaro, R.
    Sambataro, D.
    Rovelli, F.
    Vitali, C.
    Locatelli, F.
    Rutella, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 831 - 831
  • [26] Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening
    Zhang, Guoqing
    Xing, Jing
    Wang, Yulan
    Wang, Lihao
    Ye, Yan
    Lu, Dong
    Zhao, Jihui
    Luo, Xiaomin
    Zheng, Mingyue
    Yan, Shiying
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [27] Indoleamine 2,3-Dioxygenase 1 (IDO1) Expression in Biliary Tract Cancers
    Bavi, Prashant
    Hedley, David
    Knox, Jennifer J.
    Serra, Stefano
    MODERN PATHOLOGY, 2017, 30 : 160A - 161A
  • [28] Indoleamine 2,3-dioxygenase 1 (IDO1) regulates immune evasion in lymphoma
    Park, Jihyun
    Yoo, Seung-Joo
    Hu, Qianni
    Fielder, Carly M.
    Yoon, Hyundong
    Hong, Junshik
    Kim, Byung-Su
    Koh, Youngil
    Kim, Tae Kon
    Yoon, Sung-Soo
    Yan, Chi
    CANCER RESEARCH, 2024, 84 (06)
  • [29] Indoleamine 2,3-Dioxygenase 1 (IDO1) Expression in Biliary Tract Cancers
    Bavi, Prashant
    Hedley, David
    Knox, Jennifer J.
    Serra, Stefano
    LABORATORY INVESTIGATION, 2017, 97 : 160A - 161A
  • [30] Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy
    Zhang, Hongjun
    Liu, Kun
    Pu, Qinglin
    Achab, Abdelghani
    Ardolino, Michael J.
    Cheng, Mangeng
    Deng, Yongqi
    Doty, Amy C.
    Ferguson, Heidi
    Fradera, Xavier
    Knemeyer, Ian
    Kurukulasuriya, Ravi
    Lam, Yu-hong
    Lesburg, Charles A.
    Martinot, Theodore A.
    McGowan, Meredeth A.
    Miller, J. Richard
    Otte, Karin
    Biju, Purakattle J.
    Sciammetta, Nunzio
    Solban, Nicolas
    Yu, Wensheng
    Zhou, Hua
    Wang, Xiao
    Bennett, David Jonathan
    Han, Yongxin
    ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (11): : 1530 - 1536